Trial Profile
A Randomized Phase 2 Placebo-Controlled Study of LY2495655 in Patients With Advanced or Metastatic Pancreatic Cancer Receiving Chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Jan 2022
Price :
$35
*
At a glance
- Drugs Landogrozumab (Primary) ; Antineoplastics; Erlotinib; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 10 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Jul 2015 Planned End Date changed from 1 Jun 2015 to 1 Sep 2015, as reported by ClinicalTrials.gov.
- 09 Apr 2015 Planned End Date changed from 1 Feb 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov